Skip to main content

Advertisement

Table 2 Summary of plasma pro-inflammatory cytokines levels at diagnosis in patients with NSCLC

From: Plasma RANTES, IL-10, and IL-8 levels in non–small-cell lung cancer patients treated with EGFR-TKIs

Case Histrogical type EGFR mutation status Brinkman index Treatment agent Response IL-8 (ng/mL) IL-10 (ng/mL) RANTES (pg/ml)
1 Ad Ex21 L858R 900 gefitinib PR 5.79 1.67 2
2 Ad Ex21 L858R 0 erlotinib PR 3.33 94.2 1.41
3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13
4 Ad Ex21 L858R 0 gefitinib PR 3.92 18.1 1.85
5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11
6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56
7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02
8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38
9 Ad negative 400 erlotinib SD 34.9 3.39 3.66
10 Ad negative 0 erlotinib SD 27.1 4.94 2.25
11 Ad unknown 1800 erlotinib SD NE NE NE
12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98
13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66
14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5
15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7
16 La negative 2080 erlotinib SD NE NE NE
17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06
18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82
19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783
20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02
21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76
22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91
23 Sq unknown 1560 erlotinib PD NE NE NE
24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57
25 Ad unknown 0 erlotinib PD NE NE NE
26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12
27 Ad unknown 1410 erlotinib PD NE NE NE
28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89
29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16
30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292
31 Ad negative 825 erlotinib PD 8.27 1.59 2.13
32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7
33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06
  1. NSCLC, Non-small-cell lung cancer; Ad, Adenocarcinoma; Sq, Squamous cell carcinoma; La, Large-cell carcinoma; Ex, Exon; del, Deletion; PR, Partial response; SD, stable disease; PD, Progression disease; IL-8, Interleukin-8; IL-10, Interleukin-10; RANTES, Regulated upon activation normal T-cell expressed and secreted.